High Rates of HIV Infection Among Injection Drug Users Participating in Needle Exchange Programs in Montreal; Results of Cohort Study

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

High Rates of HIV Infection Among Injection Drug Users Participating in Needle Exchange Programs in Montreal; Results of Cohort Study

American Journal of Epidemiology (12/15/97) Vol. 146, No. 12, P. 994
Bruneau, J.; Lamothe, F.; Franco, E.

Abstract: Canadian researchers have concluded that participants in needle-exchange programs in Montreal appear to have greater HIV seroconversion rates than non-participants. Led by Julie Bruneau of the Centre Hospitalier de l'Universite de Montreal, the team used three risk assessment scenarios to determine the relationship between risk behaviors and HIV seroprevalence and seroincidence among injection drug users. According to the researchers--who studied nearly 1,600 participants for an average of 21.7 months--the adjusted odds ratio for HIV seroprevalence in IDUs reporting recent NEP use was 2.2. The cohort study revealed 89 incident cases of HIV infection with a cumulative probability of HIV seroconversion of 33 percent for NEP users and 13 percent for non-participants. The nested case-control study, meanwhile, suggested that consistent NEP use was linked to HIV seroconversion during follow-up. Furthermore, despite broad adjustment for confounders, the researchers note that risk elevations for HIV infection related to NEP participation were both "substantial and consistent" in the three risk assessment scenarios used for the cohort of IDUs.

971218
AD972305

Copyright © 1997 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.